Speaker Profile
M.D., EVP, Chief Medical Officer, Intellia Tx
Biography
David Lebwohl, MD is the chief medical officer at Intellia Therapeutics, a genome editing company. Before Intellia, David was the chief medical officer at Semma Therapeutics Inc. (acquired by Vertex), and led drug development teams at Novartis Pharmaceuticals and Bristol Myers Squibb. At Novartis, he was Senior Vice President and Program Head, CART Teams, responsible for the development of the breakthrough therapy Kymriah (tisagenlecleucel), approved for leukemia and lymphoma. Under his leadership, the blockbuster drug Afinitor (everolimus) was approved for metastatic breast, neuroendocrine, and kidney cancer as well as the rare genetic disease tuberous sclerosis. David received an AB in Biochemical Sciences from Harvard College and an MD from the Yale University. He completed his residency in internal medicine at Brigham and Womens Hospital in Boston and his fellowship training at Memorial Sloan Kettering Cancer Center in medical oncology and hematology.
Session Abstract – PMWC 2024 Silicon Valley
Track Co-Chairs:
Yael Weiss, Mahzi Tx
Peter Marks, FDA
- PMWC 2024 CGT Award Ceremony
Pioneer Honoree: Katherine A. High, AskBio
Pioneer Honoree: Timothy Yu, Boston Children's Hospital
- Piloting Interventional Genomics for Orphan Diseases
Keynote: Timothy Yu, Boston Children's Hospital
- Accelerated Approval for Small Populations: Biomarkers & Endpoints (PANEL)
Chair: Peter Marks, FDA
- Jennifer Puck, UCSF
- Katherine A. High, Rockefeller University
- Timothy Yu, Boston Children's Hospital - Novel Clinical Design Approaches in Rare Diseases (PANEL)
Chair: Adam Shaywitz, Bridge Bio
- Salvador Rico, Encoded Therapeutics
- Eric Crombez, Ultragenyx
- Elizabeth Berri Kravis, Rush University
- Empowering Patient Advocacy in Rare Disease Therapies (PANEL)
Chair: Yael Weiss, Mahzi Tx
- Charlene Son Rigby, STXBP1 Foundation
- Michael Graglia, Syngap Research Fund - Advancing the Frontier: Gene and Cell Therapies for Rare Diseases (PANEL)
Chair: Matthew Porteus, Stanford
- Swati Tole, Capsida Biotherapeutics
- Adrian Veres, Dyno Therapeutics
- Thomas Wechsler, J&J
- David Lebwohl, Intellia Therapeutics
- Pooja Agarwal, BioMarin Pharmaceutical
